Overview

Diabetic Gastroparesis Study 05

Status:
Terminated
Trial end date:
2020-10-05
Target enrollment:
Participant gender:
Summary
This open-label study is to assess the safety of continued treatment with Relamorelin for participants who previously completed the RLM-MD-03 or RLM-MD-04 study and to provide treatment for these participants until Relamorelin becomes commercially available or the Sponsor terminates development.
Phase:
Phase 3
Details
Lead Sponsor:
Allergan